Merkel cell carcinoma

Cellular and Molecular Life Sciences

Volumn 66, Issue 1, 2009, Pages 1-8

  Becker, J C ^a   Schrama, D ^a   Houben, R ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Carcinogenesis; Epidemiology; Neuroendocrine carcinoma of the skin; Polyomavirus; Signal transduction

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P53; RETINOBLASTOMA PROTEIN; WNT PROTEIN;

CANCER EPIDEMIOLOGY; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CLINICAL FEATURE; HISTOLOGY; HUMAN; MERKEL CELL TUMOR; NONHUMAN; POLYOMA VIRUS; SHORT SURVEY; SIGNAL TRANSDUCTION;

CARCINOMA, MERKEL CELL; HUMANS; POLYOMAVIRUS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

POLYOMAVIRUS;

EID: 58149512295     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-008-8483-6     Document Type: Short Survey

References (60)

1. Toker C. (1972) Trabecular carcinoma of the skin. Arch. Dermatol. 105, 107-110.
2. Gould V.E., Moll R., Moll I., Lee I., and Franke W.W. (1985) Neuroendocrine (Merkel) cells of the skin: hyperplasias, dysplasias, and neoplasms. Lab. Invest. 52, 334-353.
3. Girschik J., Fritschi L., Threlfall T., and Slevin T. (2008) Deaths from non-melanoma skin cancer in Western Australia. Cancer Causes Control. Epub ahead of print.
4. Weller K., Vetter-Kauzcok C., Kähler K., Hauschild A., Eigentler T., Pföhler C., Neuber K., Moll I., Krause M., Kneisel L., Nashan D., Thoelke A., Letsch B., Näher H., and Becker J.C. (2006) Guideline implementation in Merkel cell carcinoma: an example of a rare disease. Dtsch Arztebl. 103, 2791-2796.
5. Hodgson N.C. (2005) Merkel cell carcinoma: changing incidence trends. J. Surg. Oncol. 89, 1-4.
6. Heath M., Jaimes N., Lemos B., Mostaghimi A., Wang L.C., Penas P.F., and Nghiem P. (2008) Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J. Am. Acad. Dermatol. 58, 375-381.
7. Busse P.M., Clark J.R., Muse V.V., and Liu V. (2008) Case records of the Massachusetts General Hospital. Case 19-2008. A 63-year-old HIV-positive man with cutaneous Merkel-cell carcinoma. N. Engl. J. Med. 358, 2717-2723.
8. Veness M.J. and Harris D. (2007) Role of radiotherapy in the management of organ transplant recipients diagnosed with non-melanoma skin cancers. Australas. Radiol. 51, 12-20.
9. Engels E.A., Frisch M., Goedert J.J., Biggar R.J., and Miller R.W. (2002) Merkel cell carcinoma and HIV infection. Lancet 359, 497-498.
10. Richetta A.G., Mancini M., Torroni A., Lore B., Iannetti G., Sardella B., and Calvieri S. (2008) Total spontaneous regression of advanced merkel cell carcinoma after biopsy: review and a new case. Dermatol. Surg. 34, 815-822.
11. Kubo H., Matsushita S., Fukushige T., Kanzaki T., and Kanekura T. (2007) Spontaneous regression of recurrent and metastatic Merkel cell carcinoma. J. Dermatol. 34, 773-777.
12. Missotten G.S., Wolff-Rouendaal D., and de Keizer R.J. (2008) Merkel cell carcinoma of the eyelid review of the literature and report of patients with Merkel cell carcinoma showing spontaneous regression. Ophthalmology 115, 195-201.
13. Plaza J.A. and Suster S. (2006) The Toker tumor: spectrum of morphologic features in primary neuroendocrine carcinomas of the skin (Merkel cell carcinoma). Ann. Diagn. Pathol. 10, 376-385.
14. Kim J. and McNiff J.M. (2008) Nuclear expression of survivin portends a poor prognosis in Merkel cell carcinoma. Mod. Pathol. 21, 764-769.
15. Asioli S., Righi A., Volante M., Eusebi V., and Bussolati G. (2007) p63 expression as a new prognostic marker in Merkel cell carcinoma. Cancer 110, 640-647.
16. Feinmesser M., Halpern M., Fenig E., Tsabari C., Hodak E., Sulkes J., Brenner B., and Okon E. (1999) Expression of the apoptosis-related oncogenes bcl-2, bax, and p53 in Merkel cell carcinoma: can they predict treatment response and clinical outcome? Hum. Pathol. 30, 1367-1372.
17. Kennedy M.M., Blessing K., King G., and Kerr K.M. (1996) Expression of bcl-2 and p53 in Merkel cell carcinoma. An immunohistochemical study. Am. J. Dermatopathol. 18, 273-277.
18. Schlagbauer-Wadl H., Klosner G., Heere-Ress E., Waltering S., Moll I., Wolff K., Pehamberger H., and Jansen B. (2000) Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice. J. Invest. Dermatol. 114, 725-730.
19. Shah M.H., Varker K.A., Collamore M., Zwiebel J.A., Chung K.Y., Coit D., and Kelsen D. Multicenter phase II trial of bcl-2 antisense therapy (Genasense®) in patients with advanced Merkel cell carcinoma. AACR 2007 Poster presentation.
20. Chen X., Yang J., Evans P.M., and Liu C. (2008) Wnt signaling: the good and the bad. Acta Biochim. Biophys. Sin. 40, 577-594.
21. Liu S., Daa T., Kashima K., Kondoh Y., and Yokoyama S. (2007) The Wnt-signaling pathway is not implicated in tumorigenesis of Merkel cell carcinoma. J. Cutan. Pathol. 34, 22-26.
22. Vogelstein B. and Kinzler K.W. (2004) Cancer genes and the pathways they control. Nat. Med. 10, 789-799.
23. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., and Futreal P.A. (2002) Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
24. Brunner M., Thurnher D., Pammer J., Geleff S., Heiduschka G., Reinisch C.M., Petzelbauer P., and Erovic B.M. (2008) Expression of VEGF-A/C, VEGF-R2, PDGF-alpha/beta, c-kit, EGFR, Her-2/Neu, Mcl-1 and Bmi-1 in Merkel cell carcinoma. Mod. Pathol. 21, 876-884.
25. Feinmesser M., Halpern M., Kaganovsky E., Brenner B., Fenig E., Hodak E., Sulkes J., and Okon E. (2004) c-kit expression in primary and metastatic Merkel cell carcinoma. Am. J. Dermatopathol. 26, 458-462.
26. Llombart B., Monteagudo C., Lopez-Guerrero J.A., Carda C., Jorda E., Sanmartin O., Almenar S., Molina I., Martin J.M., and Llombart-Bosch A. (2005) Clinicopathological and immunohistochemical analysis of 20 cases of Merkel cell carcinoma in search of prognostic markers. Histopathology 46, 622-634.
27. Strong S., Shalders K., Carr R., and Snead D.R. (2004) KIT receptor (CD117) expression in Merkel cell carcinoma. Br. J. Dermatol. 150, 384-385.
28. Swick B.L., Ravdel L., Fitzpatrick J.E., and Robinson W.A. (2007) Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - implications for treatment with imatinib mesylate. J. Cutan. Pathol. 34, 324-329.
29. Houben R., Michel B., Vetter-Kauczok C.S., Pfohler C., Laetsch B., Wolter M.D., Leonard J.H., Trefzer U., Ugurel S., Schrama D., and Becker J.C. (2006) Absence of classical MAP kinase pathway signalling in Merkel cell carcinoma. J. Invest. Dermatol. 126, 1135-1142.
30. Worda M, Sreevidya CS, Ananthaswamy HN, Cerroni L, Kerl H, and Wolf P (2005) T1796A BRAF mutation is absent in Merkel cell carcinoma. Br. J. Dermatol. 153, 229-232.
31. Houben R., Ortmann S., and Becker J.C. (2007) RKIP does not contribute to MAP kinase pathway silencing in the Merkel Cell Carcinoma cell line UISO. J. Carcinog. 6, 16.
32. Ronan S.G., Green A.D., Shilkaitis A., Huang T.S., and Das Gupta T.K. (1993) Merkel cell carcinoma: in vitro and in vivo characteristics of a new cell line. J. Am. Acad. Dermatol. 29, 715-722.
33. Houben R., Ortmann S., Schrama D., Herold M.J., Berberich I., Reichardt H.M., and Becker J.C. (2007) Activation of the MAP kinase pathway induces apoptosis in the Merkel cell carcinoma cell line UISO. J. Invest. Dermatol. 127, 2116-2122.
34. Jansen B., Heere-Ress E., Schlagbauer-Wadl H., Halaschek-Wiener J., Waltering S., Moll I., Pehamberger H., Marciano D., Kloog Y., and Wolff K. (1999) Farnesylthiosalicylic acid inhibits the growth of human Merkel cell carcinoma in SCID mice. J. Mol. Med. 77, 792-797.
35. Kim D. and Chung J. (2002) Akt: versatile mediator of cell survival and beyond. J. Biochem. Mol. Biol. 35, 106-115.
36. Sarbassov D.D., Guertin D.A., Ali S.M., and Sabatini D.M. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101.
37. Van Gele M., Speleman F., Vandesompele J., Van Roy N., and Leonard J.H. (1998) Characteristic pattern of chromosomal gains and losses in Merkel cell carcinoma detected by comparative genomic hybridization. Cancer Res. 58, 1503-1508.
38. Fernandez-Figueras M.T., Puig L., Musulen E., Gilaberte M., Lerma E., Serrano S., Ferrandiz C., and Ariza A. (2007) Expression profiles associated with aggressive behavior in Merkel cell carcinoma. Mod. Pathol. 20, 90-101.
39. Lassacher A., Heitzer E., Kerl H., and Wolf P. (2008) p14ARF hypermethylation is common but INK4a-ARF locus or p53 mutations are rare in Merkel cell carcinoma. J. Invest. Dermatol. 128, 1788-1796.
40. Becker J.C., Ugurel S., Brocker E.B., Schrama D., and Houben R. (2006) New therapeutic approaches for solid tumors: histone deacetylase, methyltransferase and proteasome inhibitors. J. Dtsch. Dermatol. Ges. 4, 108-113.
41. Horn H.F. and Vousden K.H. (2007) Coping with stress: multiple ways to activate p53. Oncogene 26, 1306-1316.
42. Sherr C.J. (2006) Divorcing ARF and p53: an unsettled case. Nat. Rev. Cancer. 6, 663-673.
43. Popp S., Waltering S., Herbst C., Moll I., and Boukamp P. (2002) UV-B-type mutations and chromosomal imbalances indicate common pathways for the development of Merkel and skin squamous cell carcinomas. Int. J. Cancer 99, 352-360.
44. Van Gele M., Kaghad M., Leonard J.H., Van Roy N., Naeyaert J.M., Geerts M.L., Van Belle S., Cocquyt V., Bridge J., Sciot R., Wolf-Peeters C., De Paepe A., Caput D., and Speleman F. (2000) Mutation analysis of P73 and TP53 in Merkel cell carcinoma. Br. J. Cancer 82, 823-826.
45. Ortega S., Malumbres M., and Barbacid M. (2002) Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim. Biophys. Acta 1602, 73-87.
46. Chau B.N. and Wang J.Y. (2003) Coordinated regulation of life and death by RB. Nat Rev. Cancer 3, 130-138.
47. Leonard J.H. and Hayard N. (1997) Loss of heterozygosity of chromosome 13 in Merkel cell carcinoma. Genes Chromosomes Cancer 20, 93-97.
48. Shuda M., Feng H., Kwun H.J., Rosen S.T., Gjoerup O., Moore P.S., and Chang Y. (2008) T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc. Natl. Acad. Sci. U. S. A. Epub ahead of print.
49. Ullrich S.E. (2007) Sunlight and skin cancer: lessons from the immune system. Mol. Carcinog. 46, 629-633.
50. Ullrich S.E. (2005) Mechanisms underlying UV-induced immune suppression. Mutat. Res. 571, 185-205.
51. Buell J.F., Trofe J., Hanaway M.J., Beebe T.M., Gross T.G., Alloway R.R., First M.R., and Woodle E.S. (2002) Immunosuppression and Merkel cell cancer. Transplant. Proc. 34, 1780-1781.
52. Feng H., Shuda M., Chang Y., and Moore P.S. (2008) Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319, 1096-1100.
53. zur Hausen H. (2008) Novel human polyomaviruses-re-emergence of a well known virus family as possible human carcinogens. Int. J. Cancer 123, 247-250.
54. Shah K.V. (2007) SV40 and human cancer: a review of recent data. Int. J. Cancer 120, 215-223.
55. Moens U., Van Ghelue M., and Johannessen M. (2007) Oncogenic potentials of the human polyomavirus regulatory proteins. Cell Mol. Life Sci. 64, 1656-1678.
56. Caracciolo V., Reiss K., Khalili K., De Falco G., and Giordano A. (2006) Role of the interaction between large T antigen and Rb family members in the oncogenicity of JC virus. Oncogene 25, 5294-5301.
57. Ahsan N. and Shah K.V. (2006) Polyomaviruses and human diseases. Adv. Exp. Med. Biol. 577, 1-18.
58. Becker J.C., Houben R., Ugurel S., Trefzer U., Pfohler C., and Schrama D. (2008) MC polyomavirus is frequently present in Merkel cell carcinoma of European patients. J. Invest. Dermatol. Epub ahead of print.
59. Garneski K.M., Warcola A.H., Feng Q., Kiviat N.B., Leonard J.H., and Nghiem P. (2008) Merkel cell polyomavirus is more frequently present in North American than Australian Merkel cell carcinoma tumors. J. Invest Dermatol. Epub ahead of print.
60. Kassem A., Schopflin A., Diaz C., Weyers W., Stickeler E., Werner M., and Zur H.A. (2008) Frequent detection of Merkel cell polyomavirus in human Merkel cell carcinomas and identification of a unique deletion in the VP1 gene. Cancer Res. 68, 5009-5013.